Bookmark and Share
BioAssay: AID 1513

Counter Screen using XIAP-Bir3 for Chemical Antagonists of Bir1/2 domains of IAP-family anti-apoptotic proteins

This XIAP-Bir3 dose response assay is developed and performed as a counter screen for hits originally identified in the XIAP-Bir1/2 HTS binding assay (AID 1018). No primary screening was performed using this assay, only the compounds identified as positives in Bir1/2 assay were tested against Bir3. Compounds are obtained from MLSMR repository. ..more
_
   
 Tested Compounds
 Tested Compounds
All(238)
 
 
Active(3)
 
 
Inactive(235)
 
 
 Tested Substances
 Tested Substances
All(238)
 
 
Active(3)
 
 
Inactive(235)
 
 
AID: 1513
Data Source: Burnham Center for Chemical Genomics (BCCG-A129-XIAP-Bir3-Assay)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Screening Center Network
BioAssay Version:
Deposit Date: 2009-01-28
Modify Date: 2010-12-29

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 3
Related Experiments
Show more
AIDNameTypeProbeComment
1018Chemical Antagonists IAP-family anti-apoptotic proteinsConfirmatory depositor-specified cross reference
1449Chemical Antagonists of IAP-family anti-apoptotic proteins confirmationConfirmatory depositor-specified cross reference
1514Counter Screen using XIAP-Bir3 of the Chemical Antagonists of IAP-family anti-apoptotic proteins confirmation assayConfirmatory depositor-specified cross reference
1638Summary of Chemical Antagonists IAP-family anti-apoptotic proteinsSummary3 depositor-specified cross reference
1749SAR analysis of Antagonists of IAP-family anti-apoptotic proteinsConfirmatory depositor-specified cross reference
1750SAR analysis of Antagonists of XIAP-Bir3 domain of IAP-family anti-apoptotic proteinsConfirmatory depositor-specified cross reference
488957SAR analysis of Antagonists of IAP-family anti-apoptotic proteins - Set 2Confirmatory depositor-specified cross reference
488963SAR analysis of Antagonists of XIAP-Bir3 domain of IAP-family anti-apoptotic proteins - Set 2Confirmatory depositor-specified cross reference
485369SAR analysis of the effect of Antagonists of IAP-family anti-apoptotic proteins on rhTRAIL in MDA-MB-231 cellsOther same project related to Summary assay
485370SAR analysis of the effect of Antagonists of IAP-family anti-apoptotic proteins on rhTRAIL in HeLa cellsOther same project related to Summary assay
Description:
Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)
Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)
Network: NIH Molecular Libraries Screening Centers Network (MLSCN)
Grant Proposal Number: MH081277-01
Assay Provider: John C. Reed, Sanford-Burnham Medical Research Institute, San Diego, CA

This XIAP-Bir3 dose response assay is developed and performed as a counter screen for hits originally identified in the XIAP-Bir1/2 HTS binding assay (AID 1018). No primary screening was performed using this assay, only the compounds identified as positives in Bir1/2 assay were tested against Bir3. Compounds are obtained from MLSMR repository.

Apoptosis plays an essential role in many aspects of normal development and physiology, becoming dysregulated in myriad diseases characterized by insufficient or excessive cell death. Caspases are intracellular proteases that are suppressed by Inhibitor of Apoptosis Proteins (IAPs), a family of evolutionarily conserved anti-apoptotic proteins. Proteins released from mitochondria (SMAC and HtrA2) can competitively displace IAPs from the Caspases, thus helping to drive apoptosis. It has been shown that only a few residues at the N-terminus of activated SMAC protein (4-mer) are sufficient to affect the release of IAPs from Caspases. Thus, it is plausible to identify chemical compounds that mimic the effect of SMAC in antagonizing IAPs by causing them to release Caspases. Non-peptidyl chemical inhibitors would have advantages over SMAC peptides, in terms of cell permeability, stability, and in vivo pharmacology. Thus, the goal of this project is to generate small-molecule chemical probe compounds that mimic the effects of SMAC peptides, inhibiting the function of IAPs.

Basis of the assay is disruption of fluorescence polarization resulting from binding of a XIAP-BIR3 (bacoloviral IAP repeat, Bir3) domain protein derived from two of the three conserved caspase binding BIR domains of XIAP to a rhodamine tagged 7-mer N-terminal SMAC peptide.
Protocol
Bir3 assay materials:
1) Bir3 protein and rhodamine-SMAC peptide (AVPIAQK-rhodamine) were provided by Prof. John Reed (Sanford-Burnham Medical Research Institute, San Diego, CA)
2) Assay buffer: 31.25 mM HEPES-NaOH, pH 7.5, 1.25 mM TCEP, 0.00625% Tween 20.
3) Bir3 working solution contained 155 nM Bir3 in the assay buffer.
4) Rhodamine-SMAC working solution contained 50 nM AVPIAQK-rhodamine peptide in the assay buffer.

Bir3 dose-response protocol:
1) Compound were serially diluted in DMSO to have duplicate 10-point curves with 2-fold dilution between concentrations.
2) 4 uL of 100 uM compounds in 10% DMSO were dispensed in columns 3-22 of Greiner 384-well black small-volume plates (784076). Columns 1-2 and 23-24 were added with 4 uL of 10% DMSO.
2) Positive control wells, that contained no Bir3, were assigned to columns 1-2 and were added 8 uL of assay buffer using WellMate bulk dispenser (Matrix).
3) 8 uL of Bir3 working solution was added to columns 3-22 using WellMate bulk dispenser (Matrix). Negative control wells that contained no compounds were assigned to columns 23-24.
4) Plates were briefly spinned down and incubated for 1h at room temperature.
5) 8 uL of Rhodamine-SMAC working solution was added to the whole plate using WellMate bulk dispenser (Matrix).
6) Final concentrations of the components in the assay were as follows:
a. 25 mM HEPES-NaOH, pH 7.5, 1 mM TCEP, 0.005% Tween 20.
b. 20 nM Rhodamine-SMAC (columns 1-24)
c. 62 nM Bir3 (columns 3-24)
d. 2 % DMSO (columns 1-24
e. serially diluted compounds (columns 3-22)
7) Plates were incubated for 30 min at room temperature protected from direct light.
8) Fluorescence polarization was measured on an EnVision plate reader (Perkin Elemer) using rhodamine filters: excitation filter - 540 nm, emission filter - 590 nm, dichroic mirror - 560 nm. The signal for each well was acquired for 100 ms.
9) Data analysis was performed using CBIS software (ChemInnovations, Inc).
Comment
Compounds that were identified as positives in screening of Bir1/2 were tested in this assay. Compounds with an IC50 < 100 uM are considered "active."

To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the Bir3 assay is described below.

Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the Bir3 assay is as follows:

1) First tier (0-40 range) is reserved for primary screening data-and is not applicable in this assay.
2) Second tier (41-80 range) is reserved for dose-response confirmation data.
a. Inactive compounds of the confirmatory stage are assigned a score value equal 41.
b. The score is linearly correlated with a compound#s potency and, in addition, provides a measure of the likelihood that the compound is not an artifact based on the available information.
c. The Hill coefficient is taken as a measure of compound behavior in the assay via an additional scaling factor QC:
QC = 2.6*[exp(-0.5*nH^2) - exp(-1.5*nH^2)]
This empirical factor prorates the likelihood of target-specific compound effect vs. its non-specific behavior in the assay. This factor is based on expectation that a compound with a single mode of action that achieved equilibrium in the BIR3 assay demonstrates the Hill coefficient value of 1. Compounds deviating from that behavior are penalized proportionally to the degree of their deviation.
d. Summary equation that takes into account the items discussed above is
Score = 44 + 6*(pIC50 - 3)*QC,
where pIC50 is a negative log(10) of the IC50 value expressed in mole/L concentration units. This equation results in the Score values above 50 for compounds that demonstrate high potency and predictable behavior. Compounds that are inactive in the assay or whose concentration-dependent behavior are likely to be an artifact of that assay will generally have lower Score values.
A score of 44 is given to active compounds selected from plates:
a) That do not have a Hill coefficient associated with them and have a qualifier of < or >.
or
b) The value of + 6*(pIC50-3)*QC, is < 0.500
Active compounds will have a score >= 44.

3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues is not applicable to this assay
Categorized Comment - additional comments and annotations
From ChEMBL:
Assay Type: Binding
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1IC50_QualifierThis qualifier is to be used with the next TID, IC50. If qualifier is "=", IC50 result equals to the value in that column;if qualifier is ">", IC50 result is greater than that value. if qualifier is "<", IC50 result is smaller than that value.String
2IC50*IC50 value determined using sigmoidal dose response equationFloatμM
3Std.Err(IC50)Standard Error of IC50 valueFloatμM
4nHHill coefficient determined using sigmoidal dose response equationFloat

* Activity Concentration.
Additional Information
Grant Number: MH081277-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: